

# Gilles Darcis

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/1529183/gilles-darcis-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

44  
papers

819  
citations

14  
h-index

28  
g-index

52  
ext. papers

1,183  
ext. citations

6.4  
avg, IF

4.43  
L-index

#	Paper	IF	Citations
44	Retention in care and predictors of attrition among HIV-infected patients who started antiretroviral therapy in Kinshasa, DRC, before and after the implementation of the Treat-all strategy. <i>PLOS Global Public Health</i> , <b>2022</b> , 2, e0000259		0
43	Novel role of UHRF1 in the epigenetic repression of the latent HIV-1.. <i>EBioMedicine</i> , <b>2022</b> , 79, 103985	8.8	0
42	Longitudinal analysis of sociodemographic, clinical and therapeutic factors of HIV-infected individuals in Kinshasa at antiretroviral therapy initiation during 2006-2017. <i>PLoS ONE</i> , <b>2021</b> , 16, e0259073	3.7	0
41	Transmission of SARS-CoV-2 After COVID-19 Screening and Mitigation Measures for Primary School Children Attending School in Liège, Belgium. <i>JAMA Network Open</i> , <b>2021</b> , 4, e2128757	10.4	13
40	In-Depth Longitudinal Comparison of Clinical Specimens to Detect SARS-CoV-2. <i>Pathogens</i> , <b>2021</b> , 10,	4.5	2
39	Incidence and Risk Factors of COVID-19-Associated Pulmonary Aspergillosis in Intensive Care Unit-A Monocentric Retrospective Observational Study. <i>Pathogens</i> , <b>2021</b> , 10,	4.5	2
38	Progressive phasing out of baseline CD4+ cell count testing for people living with HIV in Kinshasa, Democratic Republic of the Congo. <i>Aids</i> , <b>2021</b> , 35, 841-843	3.5	3
37	Age-dependent impact of the major common genetic risk factor for COVID-19 on severity and mortality <b>2021</b> ,		5
36	complex and co-infection in a patient with acquired immunodeficiency syndrome: a case report. <i>Acta Clinica Belgica</i> , <b>2021</b> , 1-6	1.8	0
35	Survivors of COVID-19 mostly recover from tubular proteinuria and acute kidney injury after hospital discharge. <i>Journal of Nephrology</i> , <b>2021</b> , 34, 967-969	4.8	1
34	Decrease in late presentation for HIV care in Kinshasa, DRC, 2006-2020. <i>AIDS Research and Therapy</i> , <b>2021</b> , 18, 41	3	1
33	Shocking HIV-1 with immunomodulatory latency reversing agents. <i>Seminars in Immunology</i> , <b>2021</b> , 51, 101478	10.7	2
32	Long-term clinical follow-up of patients suffering from moderate-to-severe COVID-19 infection: a monocentric prospective observational cohort study. <i>International Journal of Infectious Diseases</i> , <b>2021</b> , 109, 209-216	10.5	6
31	The Current Status of Latency Reversing Agents for HIV-1 Remission. <i>Annual Review of Virology</i> , <b>2021</b> , 8, 491-514	14.6	4
30	Impact of switch from tenofovir disoproxil fumarate-based regimens to tenofovir alafenamide-based regimens on lipid profile, weight gain and cardiovascular risk score in people living with HIV. <i>BMC Infectious Diseases</i> , <b>2021</b> , 21, 910	4	0
29	Age-dependent impact of the major common genetic risk factor for COVID-19 on severity and mortality. <i>Journal of Clinical Investigation</i> , <b>2021</b> , 131,	15.9	15
28	Impact of the COVID-19 pandemic situation on HIV care in Liège, Belgium. <i>HIV Research and Clinical Practice</i> , <b>2021</b> , 22, 63-70	1.7	2

27	Detectability of HIV Residual Viremia despite Therapy Is Highly Associated with Treatment with a Protease Inhibitor-Based Combination Antiretroviral Therapy. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2020</b> , 64,	5.9	3
26	CD32CD4 T Cells Are Highly Enriched for HIV DNA and Can Support Transcriptional Latency. <i>Cell Reports</i> , <b>2020</b> , 30, 2284-2296.e3	10.6	19
25	Differences in HIV Markers between Infected Individuals Treated with Different ART Regimens: Implications for the Persistence of Viral Reservoirs. <i>Viruses</i> , <b>2020</b> , 12,	6.2	4
24	Impact of coronavirus pandemic and containment measures on HIV diagnosis. <i>Epidemiology and Infection</i> , <b>2020</b> , 148, e185	4.3	9
23	Evolution of Drug Interactions With Antiretroviral Medication in People With HIV. <i>Open Forum Infectious Diseases</i> , <b>2020</b> , 7, ofaa416	1	4
22	The Quest for Cellular Markers of HIV Reservoirs: Any Color You Like. <i>Frontiers in Immunology</i> , <b>2019</b> , 10, 2251	8.4	23
21	Applications of CRISPR/Cas9 tools in deciphering the mechanisms of HIV-1 persistence. <i>Current Opinion in Virology</i> , <b>2019</b> , 38, 63-69	7.5	4
20	The Impact of HIV-1 Genetic Diversity on CRISPR-Cas9 Antiviral Activity and Viral Escape. <i>Viruses</i> , <b>2019</b> , 11,	6.2	21
19	Dendritic cells potently purge latent HIV-1 beyond TCR-stimulation, activating the PI3K-Akt-mTOR pathway. <i>EBioMedicine</i> , <b>2019</b> , 42, 97-108	8.8	10
18	Current Status of Latency Reversing Agents Facing the Heterogeneity of HIV-1 Cellular and Tissue Reservoirs. <i>Frontiers in Microbiology</i> , <b>2019</b> , 10, 3060	5.7	46
17	Heterogeneous HIV-1 Reactivation Patterns of Disulfiram and Combined Disulfiram+Romidepsin Treatments. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2019</b> , 80, 605-613	3.1	8
16	Molecular Control of HIV and SIV Latency. <i>Current Topics in Microbiology and Immunology</i> , <b>2018</b> , 417, 1-22	3.3	10
15	Wild-type HIV infection despite PrEP: a lot to learn from a case report. <i>Lancet HIV,the</i> , <b>2018</b> , 5, e10	7.8	
14	Human Immunodeficiency Virus Resistance to Dolutegravir: Are We Looking in the Wrong Place?. <i>Journal of Infectious Diseases</i> , <b>2018</b> , 218, 2020	7	3
13	Tackling HIV Persistence: Pharmacological versus CRISPR-Based Shock Strategies. <i>Viruses</i> , <b>2018</b> , 10,	6.2	14
12	The Molecular Biology of HIV Latency. <i>Advances in Experimental Medicine and Biology</i> , <b>2018</b> , 1075, 187-212	5.26	33
11	Factors associated with late presentation for HIV care in a single Belgian reference center: 2006-2017. <i>Scientific Reports</i> , <b>2018</b> , 8, 8594	4.9	19
10	HIV Latency: Should We Shock or Lock?. <i>Trends in Immunology</i> , <b>2017</b> , 38, 217-228	14.4	109

9	Recurrence of visceral and muco-cutaneous leishmaniasis in a patient under immunosuppressive therapy. <i>BMC Infectious Diseases</i> , <b>2017</b> , 17, 478	4	12
8	The effect of treatment simplification on HIV reservoirs. <i>Lancet HIV,the</i> , <b>2017</b> , 4, e328-e329	7.8	7
7	Reactivation capacity by latency-reversing agents ex vivo correlates with the size of the HIV-1 reservoir. <i>Aids</i> , <b>2017</b> , 31, 181-189	3.5	27
6	Exploring the link between innate immune activation and thymic function by measuring sCD14 and TRECs in HIV patients living in Belgium. <i>PLoS ONE</i> , <b>2017</b> , 12, e0185761	3.7	12
5	Preclinical shock strategies to reactivate latent HIV-1: an update. <i>Current Opinion in HIV and AIDS</i> , <b>2016</b> , 11, 388-93	4.2	25
4	Sequential treatment with 5-aza-2'-deoxycytidine and deacetylase inhibitors reactivates HIV-1. <i>EMBO Molecular Medicine</i> , <b>2016</b> , 8, 117-38	12	58
3	Louse-borne relapsing fever in a refugee from Somalia arriving in Belgium. <i>Journal of Travel Medicine</i> , <b>2016</b> , 23,	12.9	6
2	Epigenetic control of HIV-1 post integration latency: implications for therapy. <i>Clinical Epigenetics</i> , <b>2015</b> , 7, 103	7.7	75
1	An In-Depth Comparison of Latency-Reversing Agent Combinations in Various In Vitro and Ex Vivo HIV-1 Latency Models Identified Bryostatatin-1+JQ1 and Ingenol-B+JQ1 to Potently Reactivate Viral Gene Expression. <i>PLoS Pathogens</i> , <b>2015</b> , 11, e1005063	7.6	188